Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

Clinical and Translational Oncology, 05/15/2012

The results indicated that serum M65 values elevated in advanced non–small–cell lung cancer (NSCLC) compared to a healthy control group and elevated serum M65 level can predict progression–free survival (PFS) in patients.

Print Article Summary Cat 2 CME Report